Department of Senological, Gynecological, Plastic and Reconstructive Surgery - Paris Professor Fabrice Lecuru - Institut Curie

Ovarian cancer

  • Ovarian cancer - Treatments

    Treatments

    We only discuss here epithelial tumors and mainly high-grade serous cancers.

    The treatment of ovarian cancer combines surgery, chemotherapy almost constantly and frequently new treatments that have recently appeared such as an anti-angiogenic (bevacizumab or AVASTIN), or a PARP inhibitor (olaparib or LYNPARZA, niraparib or ZEJULA, rucaparib or RUBRACA).

    Surgery is an important treatment for ovarian cancer. Its objective is to remove all of the tumor present in the ovaries, small pelvis and abdomen. It is then said to be complete. For the early stages, affecting only one ovary, it may be the only treatment needed.

    Chemotherapy is the other important treatment for ovarian cancer. It usually combines two drugs (paclitaxel TAXOL and carboplatin CARBOPLATIN) and aims to treat any remaining cancer cells after surgery.

    Anti-angiogenic treatment (bevacizumab or AVASTIN) aims to modulate the vascularization of tumor areas. It is given as an adjunct to chemotherapy.

    PARP inhibitors modulate DNA repair. They are indicated in patients whose cancer is due to a hereditary predisposition (genetic mutation) or in patients whose cancers are biologically similar.

    The choice of treatments, their association, their sequences, is decided according to the stage, the grade, the presence of a genetic mutation etc. It is therefore a “personalized” treatment.

About us

After 20 years spent at the Georges Pompidou European Hospital, I preferred to continue my activity at the Institut Curie Paris.

I joined the team of Pr Fabien REYAL (Department of Senological, Gynecological and Reconstructive Surgery)

I follow my activity of Gynecological Oncological Surgery and Recourse Surgery there.

The objective remains to provide the best possible care to women with gynecological cancers,
  - By ensuring the welcome, listening and respect for the quality of life,
  - By providing access to therapeutic innovation and clinical research.
  - Consultations take place on Wednesday afternoon and Friday morning.

Make an appointment

Choose the way you want to make an appointment with Professor Lecuru's service.

Address

Institut Curie Paris

Institutional Partners

  • Chirurgie Curie Institut Curie
  • DIU DIU Européen d'Oncologie Gynécologique et Mammaire
  • SFCO Société Française de Chirurgie Oncologique
  • IMAGYN Initiative des malades atteintes de cancers gynécologiques

Scientific Partners

IMAGYN
ONCOSTREAM
YKSI Production
TMRG
© Copyright - The site is managed in partnership with the French Institute of Gynecology. It is an information and communication tool intended for the general public, patients and health professionals in particular, in accordance with the Code of medical ethics and the recommendations of the National Council of the Order of Physicians, concerning the medical ethics on the health web, adopted in a report of May 22, 2008. The information or advice contained therein is intended to inform the FRENCH public, in simplified terms, of the current state of medical science, its pathways of research and its advances. In no case may this information or advice exonerate health professionals or patients from a real consultation with an anamnesis and a clinical examination, which alone can lead to a diagnosis and a prescription.
Haut